PALM INTRANET

Day : Tuesday
Date: 8/26/2003
Time: 15:02:58

Inventor Name Search Result

Your Search was:

Last Name = OTTOSEN
First Name = ERIK

Application#	Patent#	Status	Date Filed	Title	Inventor Name
60434798	Not Issued	020	12/20/2002	NOVEL AMINOBENZOPHENONE COMPOUNDS	OTTOSEN, ERIK RYTTER
60315025	Not Issued	020	08/28/2001	POLAR AMINOBENZOEPHENONES 614/LAC	OTTOSEN, ERIK RYTTER
60169333	Not Issued	159	12/06/1999	AMINOBENZOPHENONES AS INHIBITORS OF IL-1B AND TNF-A	OTTOSEN , ERIK R
60144169	Not Issued	159	07/16/1999	AMINOBENZOPHENONES AS INHIBITORS OF IL-1 BETA AND TNF-ALPHA	OTTOSEN , ERIK RYTTER
60144168	Not Issued	159	07/16/1999	COMPOUNDS FOR MEDICAL TREATMENT	OTTOSEN , ERIK RYTTER
60144166	Not Issued	159	07/16/1999	AMINOBENXOPHENONES AS INHIBITORS OF IL-1 BETA AND TNF-ALPHA	OTTOSEN , ERIK RYTTER
60144065	Not Issued	159	07/16/1999	COMPOUNDS FOR MEDICAL TREATMENT	OTTOSEN , ERIK RYTTER
60144063	Not Issued	159	07/16/1999	AMINOBENZOPHENONES AS INHIBITORS OF IL-1B AND TNF-@	OTTOSEN , ERIK RYTTER
60144062	Not Issued	159	07/16/1999	AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN , ERIK
10228954	Not Issued	041	08/28/2002	NOVEL AMINOBENZOEPHENONES	OTTOSEN, ERIK RYTTER
10061204	Not Issued	093	02/04/2002	CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER

10031075	6566554	150	02/22/2002	AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
10031071	6555710	150	03/15/2002	AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
10030970	Not Issued	030	02/22/2002	AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
10030965	Not Issued	095	02/22/2002	NOVEL AMINOBENZOPHENONES	OTTOSEN, ERIK RYTTER
10030941	Not Issued	090	02/22/2002	AMINOBENZOPHENONES AS INHIBITORS OF IL-BETA AND TNF-ALPHA	OTTOSEN, ERIK RYTTER
09787532	6541670	150	03/20/2001	AMINOBENZOPHENONES AS INHIBITORS OF IL 1B AND TNF	OTTOSEN, ERIK RYTTER
09424655	6121297	150	11/26/1999	CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN , ERIK RYTTER
09424631	6346520	150	11/26/1999	CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN, ERIK RYTTER
09424630	6197797	150	11/26/1999	CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN , ERIK RYTTER
09424581	6303641	150	11/26/1999	CYANOAMIDINES AS CELL PROLIFERATION INHIBITORS	OTTOSEN , ERIK RYTTER
09341923	6313174	150	07/21/1999	AMINOBENZOPHENONES AS INHIBITORS OF INTERLEUKIN AND TNF	OTTOSEN , ERIK RYTTER
08411634	5554599	150	04/11/1995	22-THIO VITAMIN D DERIVATIVES	OTTOSEN , ERIK R

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Ottosen **First Name** Erik

Search

To go back use Back button on your browser toolbar.

10/030,970

=> d ibib abs hitstr 1-3

CAS 8/26/03

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:173569 CAPLUS
DOCUMENT NUMBER: 138:221352
TITLE: Preparation of (phenylamino)benzophenones for treatment of inflammatory diseases
INVENTOR(S): Ottosen, Erik Rytter; Horneman, Anne Marie; Liang, Xifu
PATENT ASSIGNEE(S): Leo Pharma A/S, Den.
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018535	A2	20030306	WO 2002-DK557	20020826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003119902	A1	20030626	US 2002-228954	20020828

PRIORITY APPLN. INFO.: US 2001-315025P P 20010828
DK 2002-189 A 20020208

OTHER SOURCE(S): MARPAT 138:221352
GI



I



II

AB Title compds. I [wherein X = O, S, or N(ORc); R1 = halo, OH, SH, CF3, NH2, alkyl, olefinic group, alkoxy, alkylthio, alkylamino, alkoxycarbonyl, CN, CONH2, Ph, or NO2; R2 = H or R1; R3 = H, halo, OH, SH, CF3, CN, CO2H, carbamoyl, NO2, alkyl, olefinic group, cyclic hydrocarbon, alkoxy, alkylthio, alkoxycarbonyl, or Ph; R4 = H, alkyl, olefinic group, cyclic hydrocarbon, or CO2CRdReOCOR14; R5 = H or R1; R6 = (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkyl, olefinic group, alkynyl, Y1R21, Y2R22, or Y4R24; R14 = (un)substituted alkyl, olefinic group, cyclic hydrocarbon, heterocyclyl, or alkynyl; Y1 = NRaCSNRb, CO,CS, CSO, COS, CS2, OCS, OCO, NRaCSO, SO2O, SO2NRa, N=CRa, etc.; R21 = (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkyl, olefinic group, or alkynyl; Y2 = O, S, CO2, or CONRa; R22 and R24 = independently (un)substituted (alkyl)heterocyclyl, (alkyl)cyclic hydrocarbon, alkynyl, alkyl, or olefinic group; Y4 = NRaCONRbCHRc, NRaCONRbSO2, NRa, etc.; Ra, Rb, and Rc = independently H or (un)substituted alkyl, olefinic group, cyclic hydrocarbon, aryl, heterocyclyl, or alkynyl; Rd and Re = independently (un)substituted H, alkyl, olefinic group, or cyclic hydrocarbon; and pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as inhibitors of interleukin 1.beta. and tumor necrosis factor .alpha. (no data). For example, (4-amino-2-chlorophenyl)(2-methylphenyl)methanone was coupled with 2-[2-(2-bromophenyl)ethoxy]tetrahydro-2H-pyran in the presence of Cs2CO3, Pd2(dba)3, and rac-BINAP in dioxane to give II. I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory diseases, such as asthma, allergy, arthritis, gout, atherosclerosis, psoriasis, AIDS, osteoporosis, and acne (no data).

IT **500875-79-6P**, 2-[[[[5-Bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]amino]ethyl 2-methylacrylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiinflammatory agent; prepn. of (phenylamino)benzophenones for treatment of inflammatory diseases)

RN 500875-79-6 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[[5-bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)



Inventor

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:63961 CAPLUS

DOCUMENT NUMBER: 134:115759

TITLE: Preparation of aminobenzophenones as inhibitors of IL-1.beta. and TNF-.alpha.

INVENTOR(S): Ottosen, Erik Rytter

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.

SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005751	A1	20010125	WO 2000-DK387	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1210325	A1	20020605	EP 2000-943701	20000711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-144062P P 19990716
WO 2000-DK387 W 20000711
OTHER SOURCE(S): MARPAT 134:115759
GI



I



II

AB The title compds. [I; R1, R2 = halo, OH, SH, etc.; R3 = H, halo, OH, etc.; R4 = H, alkyl, allyl; Q = a bond, SO2, CR6R7OC:O (wherein R6, R7 = H, CF3, alkyl); Y = alkyl, alkenyl, cycloalkyl, etc.; X = O, S] which are able to inhibit the prodn. of IL-1.beta., TNF-.alpha. and PMN-superoxide, were prepd. and formulated. Thus, reacting 4-(2-aminophenylamino)-2-chloro-2'-

methylbenzophenone with cyclohexyl isocyanate in EtOAc afforded the urea II which showed IC50 of 13 nM and of 5.0 nM against IL-1.beta. and TNF-.alpha. prodn., resp.

IT **321438-17-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aminobenzophenones as inhibitors of IL-1.beta. and TNF-.alpha.)

RN 321438-17-9 CAPLUS

CN .beta.-Alanine, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **321438-07-7P 321438-08-8P 321438-09-9P**
321438-10-2P 321438-11-3P 321438-12-4P
321438-13-5P 321438-14-6P 321438-15-7P
321438-16-8P 321438-18-0P 321438-19-1P
321438-20-4P 321438-21-5P 321438-22-6P
321438-23-7P 321438-24-8P 321438-25-9P
321438-26-0P 321438-27-1P 321438-28-2P
321438-29-3P 321438-30-6P 321438-31-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminobenzophenones as inhibitors of IL-1.beta. and TNF-.alpha.)

RN 321438-07-7 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 321438-08-8 CAPLUS

CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-09-9 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 321438-10-2 CAPLUS
CN Urea, N-butyl-N'-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 321438-11-3 CAPLUS
CN Benzenesulfonamide, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 321438-12-4 CAPLUS

CN Benzenesulfonamide, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 321438-13-5 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 321438-14-6 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 321438-15-7 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 321438-16-8 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 321438-18-0 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-19-1 CAPLUS
CN .beta.-Alanine, N-[[[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 321438-20-4 CAPLUS
CN Urea, N-[2-[[3-chloro-4-(2-methylbenzoyl)phenyl]amino]-5-fluorophenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-21-5 CAPLUS
CN Urea, N-[5-bromo-2-[[4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-22-6 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,5-dimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-23-7 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-24-8 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-25-9 CAPLUS
CN Urea, N-[5-bromo-2-[[3-ethoxy-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-26-0 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-27-1 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,3-dimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-28-2 CAPLUS
CN Urea, N-[5-bromo-2-[[3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-29-3 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-30-6 CAPLUS
CN Urea, N-[5-bromo-2-[[3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 321438-31-7 CAPLUS
CN Urea, N-[5-bromo-2-[[3-fluoro-4-(2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:527309 CAPLUS
DOCUMENT NUMBER: 129:148822
TITLE: Preparation and formulation of aminobenzophenones as inhibitors of interleukin and TNF
INVENTOR(S): Ottosen, Erik Rytter; Rachlin, Schneur
PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832730	A1	19980730	WO 1998-DK8	19980108
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854781	A1	19980818	AU 1998-54781	19980108
AU 733561	B2	20010517		
EP 966424	A1	19991229	EP 1998-900270	19980108

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

NZ 336754	A	20010330	NZ 1998-336754		19980108
JP 2001511771	T2	20010814	JP 1998-531499		19980108
RU 2200153	C2	20030310	RU 1999-118221		19980108
US 6313174	B1	20011106	US 1999-341923		19990721
PRIORITY APPLN. INFO.:			GB 1997-1453	A	19970124
			WO 1998-DK8	W	19980108

OTHER SOURCE(S): MARPAT 129:148822

GI



I

AB The title compds. I [R1 and R2 stand independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, Ph, or nitro; R3 stands for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, Ph, cyano, carboxy, or carbamoyl; R4, R5 and R6 stand independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxycarbonyl, or alkyloxo, the C-content of which can be from 1 to 5; X stands for oxygen, NOH, NO-alkyl, dialkoxy, cyclic dialkoxy, dialkylthio, or cyclic dialkylthio, the C-content of which can be from 1 to 5] are prepd. The present compds. are of value in the human and veterinary practice as systemic and topical therapeutic agents for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis. In an in vitro test using human polymorphonuclear granulocytes, 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone in vitro showed IC50 of 13 nM and 7.1 nM against the prodn. of Il-1.beta. and TNF-.alpha., resp. In the above test, 4-(2-aminophenylamino)benzophenone (II) in vitro showed IC50 of 250 nM and 790 nM against the prodn. of Il-1.beta. and TNF-.alpha., resp. In the 12-O-tetradecanoylphorbol-13-acetate induced murine skin inflammation model, II showed activity equal to hydrocortisone.

IT **210965-94-9P 210966-54-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminobenzophenones as inhibitors of interleukin and TNF)

RN 210965-94-9 CAPLUS

CN Urea, N-[2-[(4-benzoylphenyl)amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 210966-54-4 CAPLUS
CN Urea, N-[2-[(4-benzoylphenyl)amino]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:01:13 ON 26 AUG 2003)

FILE 'REGISTRY' ENTERED AT 15:01:19 ON 26 AUG 2003
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 28 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:10 ON 26 AUG 2003
L4 3 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.